HKEX Stock Code: 01093English|繁體|简体

2024 Results

  • Revenue RMB29,009M, -7.8%
  • Underlying profit attributable to shareholders RMB4,683M, -25.4%
  • Reported profit attributable to shareholders RMB4,328M, -26.3%
  • Basic earnings per share (underlying profit) RMB39.90 cents, -24.5%
  • Basic earnings per share (reported) RMB36.87 cents, -25.5%

Financial Reports

2024 Interim Report

Highlight - 2024 Results

Revenue
RMB29,009M, -7.8%
Underlying profit attributable to shareholders
RMB4,683M, -25.4%
Reported profit attributable to shareholders
RMB4,328M, -26.3%
Basic earnings per share (reported)
RMB39.90 cents, -24.5%
Basic earnings per share (underlying profit)
RMB36.87 cents, -25.5%

Corporate Governance

Corporate Governance

Latest News

Apr
25
VOLUNTARY ANNOUNCEMENT - SYH2068 INJECTION (A DOUBLE-STRANDED SMALL INTERFERING RNA DRUG) OBTAINS CLINICAL TRIAL APPROVAL
Apr
23
UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE THREE MONTHS ENDED 31 MARCH 2025
Apr
22
VOLUNTARY ANNOUNCEMENT - PRUSOGLIPTIN AND METFORMIN EXTENDED-RELEASE TABLETS OBTAINS CLINICAL TRIAL APPROVAL

Financial Calendar

Mar
28
2024 Annual Results Announcement
Mar
28
Board Meeting
* Subject to change.
>> more

Financial Reports

Financial Reports

Financial Summary

Financial Summary

IR Contacts

Address : Suite 3206, 32/F, Central Plaza,
18 Harbour Road, Wanchai, Hong Kong
Tel : (852) 2500 3144
Fax : (852) 2802 4552
E-mail : ir@cspc.hk
© Copyright 2025 CSPC Pharmaceutical Group Limited. All Rights Reserved.
Disclaimer